Safety and Efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese Patients with Reflux Esophagitis

Internal Medicine

Volumn 50, Issue 3, 2011, Pages 179-188

  Fujimoto, Kazuma ^a   Hongo, Michio ^b  

^a SAGA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Rabeprazole; Reflux esophagitis

Indexed keywords

GASTRIN; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCHROMAFFIN LIKE CELL; ESOPHAGOSCOPY; FEMALE; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; LABORATORY TEST; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RECURRENCE RISK; REFLUX ESOPHAGITIS; SIDE EFFECT; SKIN TOXICITY; STOMACH CARCINOID; STOMACH GLAND POLYP; STOMACH MUCOSA ATROPHY; STOMACH MUCOSA LESION; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; URTICARIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS, PEPTIC; FEMALE; GASTRIC MUCOSA; GASTRINS; GASTROESOPHAGEAL REFLUX; HUMANS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 79551708695     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4238     Document Type: Article

References (40)

1. N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101: 1900-1920, 2006.
2. Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology 39: 322-324, 1992.
3. The Japanese Society of Gastroenterololgy. Guideline for treatment of gastro-esophageal reflux disease. Nankodo, Tokyo, 2009 (in Japanese).
4. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 135: 1383-1391, 2008.
5. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334: 1018-1022, 1996.
6. Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol 108 (Suppl): 53-69, 1985.
7. Kazumori H, Ishihara S, Kawashima K, Fukuda R, Chiba T, Kinoshita Y. Analysis of gastrin receptor gene expression in proliferating cells in the neck zone of gastric fundic glands using laser capture microdissection. FEBS lett 489: 208-214, 2001.
8. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118: 661-669, 2000.
9. K, Dekker W, Mulder CJ, Nusteling K; Dutch Study Group. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 15: 1819-1826, 2001.
10. Bardhan KD, Cherian P, Bishop AE, et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol 96: 1767-1776, 2001.
11. Thjodleifsson B, Rindi G, Fiocca R, et al. A randomized, doubleblind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastrooesophageal reflux disease over 5 years. Aliment Pharmacol Ther 17: 343-351, 2003.
12. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102: 760-766, 1992.
13. Kikuchi S, Nakajima T, Kobayashi O, et al. Effect of age on the relationship between gastric cancer and Helicobacter pylori. Tokyo Research Group of Prevention for Gastric Cancer. Jpn J Cancer Res 91: 774-779, 2000.
14. Furukawa N, Iwakiri R, Koyama T, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol 34: 441-444, 1999.
15. Inamori M, Togawa J, Nagase H, et al. Clinical characteristics of Japanese reflux esophagitis patients as determined by Los Angeles classification. J Gastroenterol Hepatol 18: 172-176, 2003.
16. Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 69: 1373-1401, 2009.
17. K, Hongo M; The Maintenance Study Group. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. J Gastroenterol 45: 1193-1200, 2010.
18. Hongo M, Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J. Gastroenterol 45: 618-624, 2010.
19. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 111: 85-92, 1996.
20. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastrotos. Endoscopy 1: 87-97, 1969.
21. Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 93: 569-573, 1998.
22. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 22: 193-202, 2005.
23. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117: 11-16, 1999.
24. Yamaguchi K, Iwakiri R, Hara M, et al. Reflux esophagitis and Helicobacter pylori infection in patients with scleroderma. Intern Med 47: 1555-1559, 2008.
25. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 44: 518-534, 2009.
26. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 17: 1481-1491, 2003.
27. Okamoto K, Iwakiri R, Mori M, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci 48: 2237-2241, 2003.
28. Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc 54: 1537-1542, 2006.
29. Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 39: 888-891, 2004.
30. Danjo A, Yamaguchi K, Fujimoto K, et al. Comparison of endoscopic findings with symptom assessment system (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol 24: 633-638, 2009.
31. Maekawa T, Kinoshita Y, Okada A, et al. Relationship between severity and symptoms of reflux oesophagitis in elderly patients in Japan. J Gastroenterol Hepatol 13: 927-930, 1998.
32. Joh T, Miwa H, Higuchi K, et al. Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol 42: 444-449, 2007.
33. Miwa H, Sasaki M, Furuta T, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 126: 69-77, 2007.
34. Yoshihara K, Yamaguchi K, Kuroki T, et al. Dysphgia in adult Japanese is not equivalent to the grade of endoscopic reflux esophagitis. Intern Med 46: 1951-1955, 2007.
35. Takashima T, Yamaguchi K, Hara M, et al. Brief questioning by nursing staffs before endoscopic examination may not always pick up clinical symptoms of endoscopic reflux esophagitis. J Clin Biochem Nutr 46: 229-233, 2010.
36. Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 126: 660-664, 2004.
37. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 53: 12-20, 2004.
38. Rindi G, Fiocca R, Morocutti A, et al. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol 17: 559-566, 2005.
39. Ohkusa T, Maekawa T, Arakawa T, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther 21: 1331-1339, 2005.
40. Danks A, Holmes P, Sparrow S, et al. 52-week oral (gavage) toxicity study with 26-week reversibility period in rats with E3810. GI Research 1 (Suppl): 557-573, 1993.